IRVING, Texas, Nov. 3, 2023 – Vizient, Inc. appreciates the Centers for Medicare and Medicaid Services (CMS) for finalizing its rule outlining how the agency plans to restore payments to hospitals that had reimbursement unlawfully reduced for drugs purchased through the 340B Drug Pricing Program from 2018 through a majority of 2022.
Vizient is pleased impacted 340B hospitals will be repaid through a one-time lump sum payment in early 2024. However, we are deeply disappointed with the agency's decision to maintain budget neutrality for the years the cuts were in effect. As Vizient previously iterated, hospitals should not have to endure reduced payments as a result of the agency's unlawful policies.
About Vizient, Inc.
Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers, and more than 25% of the non-acute care market. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume. Vizient's solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.